Seelos Therapeutics (SEEL) News Today → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free SEEL Stock Alerts $0.29 -0.02 (-6.54%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSEEL Stock Earnings: Seelos Therapeutics Beats EPS for Q4 2023investorplace.com - March 22 at 3:12 PMOptimistic Buy Rating for Seelos Therapeutics Amid Promising Drug Trial Resultsmarkets.businessinsider.com - March 20 at 5:39 PMSeelos: Phase 2/3 HEALEY ALS Trial Fails To Meet Statistical Significance In Endpointsmarkets.businessinsider.com - March 19 at 10:34 PMSeelos Therapeutics Shares Drop 47% After SLS-005 Trial Misses Primary Endpointsmarketwatch.com - March 19 at 10:34 PMNasdaq Down 100 Points; US Housing Starts Surge In Februarymarkets.businessinsider.com - March 19 at 5:34 PMCNS Disorder-Focused Seelos Therapeutics Plunges To 52-Week Low - Here's Whymsn.com - March 19 at 5:34 PMSeelos says ALS treatment fails in mid-stage studyreuters.com - March 19 at 5:34 PMUPDATE 2-Seelos Therapeutics' ALS treatment fails mid-stage studyfinance.yahoo.com - March 19 at 5:34 PMSeelos falls as lead drug fails in ALS trialmsn.com - March 19 at 9:35 AMSeelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)prnewswire.com - March 19 at 8:15 AMSeelos Therapeutics Inc.thestreet.com - February 9 at 11:53 AMSeelos Therapeutics, Inc. (SEEL)ca.finance.yahoo.com - February 1 at 12:51 PMSeelos Therapeutics Issues Common Warrants to Investorsmsn.com - January 31 at 3:52 PMSeelos Therapeutics Strikes $4M Direct Offering Dealmsn.com - January 31 at 10:18 AMSeelos Therapeutics Announces $4 Mln Direct Offering And Private Placement Of Sharesmarkets.businessinsider.com - January 26 at 9:42 PMSeelos Therapeutics Shares Hit 52-Week Low After Direct Offering Pricesmarketwatch.com - January 26 at 9:42 PMSeelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rulesfinance.yahoo.com - January 26 at 9:42 PMSeelos Therapeutics Says Received Minutes From End Of Phase II Meeting With FDAmarkets.businessinsider.com - January 22 at 10:13 AMSeelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002finance.yahoo.com - January 22 at 10:13 AMTherapy’s New Frontier: 3 Psychedelic Stocks for the Mental Health Revolutionfinance.yahoo.com - January 17 at 2:18 AMSeelos Therapeutics, Inc. (SEEL) stock forecast and price targetfinance.yahoo.com - January 16 at 9:17 PMSeelos Therapeutics Inc SEELmorningstar.com - January 5 at 2:28 PMSeelos Therapeutics: ISS Recommends Stockholders Vote For All Proposals - Quick Factsmarkets.businessinsider.com - January 2 at 1:10 PMLeading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024finance.yahoo.com - January 2 at 8:09 AMSeelos Therapeutics, Inc. Releases Letter to its Stockholdersfinance.yahoo.com - December 22 at 9:07 AM11 Most Promising Psychedelic Stocks According to Hedge Fundsfinance.yahoo.com - December 20 at 3:30 PMSeelos Therapeutics files for $250M mixed shelfmsn.com - December 18 at 8:02 PMSeelos Therapeutics (SEEL) Price Target Increased by 2900.00% to 122.40msn.com - December 16 at 3:27 PMInsider Spends US$100k Buying More Shares In Seelos Therapeuticsfinance.yahoo.com - December 4 at 8:19 AMInsider Buying: CFO Michael Golembiewski Acquires 83,000 Shares of Seelos Therapeutics Inc (SEEL)finance.yahoo.com - December 2 at 8:16 AMSeelos Therapeutics Announces Closing of Public Offeringfinance.yahoo.com - December 1 at 8:21 PMThinking about buying stock in Neximmune, ShiftPixy, Ampio Pharmaceuticals, Seelos Therapeutics, or Nio Inc?benzinga.com - December 1 at 10:20 AMThinking about buying stock in RedHill Biopharma, Mynaric, Energy Transfer LP, Seelos Therapeutics, or Petco Health and Wellness?benzinga.com - November 29 at 10:25 AMSeelos Therapeutics Shares Slide Premarket After Public Offeringmarketwatch.com - November 29 at 10:25 AMWhy Is Seelos Therapeutics (SEEL) Stock Down 42% Today?investorplace.com - November 29 at 10:02 AMSeelos Therapeutics Announces Pricing Of $5.55 Mln Public Offering; Stock Dropsmarkets.businessinsider.com - November 28 at 11:37 PMSeelos Therapeutics commences a public offering of its sharesmsn.com - November 28 at 6:37 PMSeelos Therapeutics Announces Proposed Public Offeringfinance.yahoo.com - November 28 at 6:37 PMSeelos stock falls 23% following 1-for-30 reverse splitmsn.com - November 28 at 1:36 PMSeelos Therapeutics, Iterum Therapeutics among healthcare moversmsn.com - November 28 at 1:36 PMmarketbeat.com - November 28 at 6:05 AMDefense Dept. Funds Ketamine Study For PTSD Treatment In 600 Service Members & Veteransmsn.com - November 27 at 5:33 PMSeelos' SLS-002 To Be Included In DOD's Trial To Evaluate Potential Treatments For PTSDmarkets.businessinsider.com - November 27 at 9:08 AMSeelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder (PTSD)finance.yahoo.com - November 27 at 9:08 AMSeelos to Implement 1-for-30 Reverse Stock Splitmarketwatch.com - November 24 at 1:42 PMWhy Seelos Therapeutics Shares Are Diving Todaybenzinga.com - November 24 at 1:42 PMSeelos Therapeutics Announces 1-for-30 Reverse Stock Splitfinance.yahoo.com - November 24 at 1:42 PMDole (DOLE) Q3 Earnings Top Estimatesmsn.com - November 16 at 12:14 PMSeelos Therapeutics (SEEL) Price Target Increased by 60.00% to 4.08msn.com - November 1 at 2:30 PMSeelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023finance.yahoo.com - October 27 at 12:45 PM Get Seelos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SEEL and its competitors with MarketBeat's FREE daily newsletter. Email Address World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea. Click here to find out what to do. SEEL Media Mentions By Week SEEL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SEEL News Sentiment▼0.000.41▲Average Medical News Sentiment SEEL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SEEL Articles This Week▼02▲SEEL Articles Average Week Get Seelos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SEEL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: KA News Today ALZN News Today XCUR News Today SONN News Today CPHI News Today GTBP News Today LMDX News Today OGEN News Today SNPX News Today DRUG News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SEEL) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seelos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
